The EFNB1 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MES-OV human ovarian cancer cell line, featuring targeted disruption of the EFNB1 gene. EFNB1 encodes Ephrin-B1, a transmembrane ligand that mediates bidirectional signaling with EphB receptors, processes critical for cell adhesion, repulsion, and migration. The polyclonal format provides a heterogeneous pool of gene-edited cells, facilitating robust functional studies while circumventing clonal selection artifacts often observed with monoclonal lines. This product enables precise examination of Ephrin-B1 function in cancer biology and developmental signaling.
The parental MES-OV cell line is a mesenchymal subtype of human ovarian adenocarcinoma and is widely recognized as a model for ovarian cancer metastasis and epithelial-mesenchymal transition (EMT). These cells exhibit a highly invasive phenotype and are instrumental in dissecting molecular mechanisms underlying tumor cell dissemination. Their mesenchymal characteristics offer a physiologically relevant context for assessing how loss of Ephrin-B1 function impacts migration, invasion, and the dynamic balance between epithelial and mesenchymal states.
Ephrin-B1 functions as a ligand for EphB receptors, including EphB1, EphB2, and EphB4, and initiates bidirectional signaling upon receptor binding. Forward signaling through EphB kinases activates Src family kinases, FAK, and Rho GTPases such as Rac1 and RhoA, while reverse signaling recruits adaptor proteins like Grb4, PDZ-RGS3, syntenin, and GIT1. These pathways converge on MAPK/ERK and JNK cascades and are tightly regulated by upstream cues from WNT, FGF, and HOX transcription factors. This intricate network governs cytoskeletal reorganization and cell-cell interactions essential for tissue morphogenesis and cancer progression.
Disruption of EFNB1 in MES-OV cells is expected to abrogate Ephrin-B1?Cmediated bidirectional signaling, thereby perturbing the adhesive and migratory properties critical for ovarian cancer cell invasion. Loss of Ephrin-B1 may alter interactions with EphB receptors and downstream effectors such as FAK and ERK1/2, potentially modulating the mesenchymal-invasive phenotype and EMT program. This model provides a powerful tool to examine how Ephrin-B1 deficiency influences the signaling landscape that drives metastatic behavior in ovarian cancer.
Applications of the EFNB1 Knockout MES-OV Polyclonal Cells encompass the study of ovarian cancer metastasis, validation of Ephrin-B1 as a therapeutic target, and investigation of EMT regulation, as well as research into craniofacial developmental disorders like craniofrontonasal syndrome. Typical experimental approaches include confirmation of gene disruption via Western blotting or RT-qPCR, quantitative analysis of EMT markers, functional assessment using Transwell migration and invasion assays, and signaling studies through phosphorylation-specific detection of ERK1/2 and Src kinases. Immunofluorescence can be employed to visualize EphB receptor localization, while xenograft tumor models enable in vivo evaluation of metastatic potential. For additional technical support or custom inquiries, please contact Ascent Research.
